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Patents as Business Intelligence Tools
Amy Jansen, Business Librarian Sacred Heart University Library, Fairfield, CT
As most entrepreneurs and business owners can tell you, one of the most significant
considerations that companies face is how to protect their work. Managing intellectual property
is now integrated with overall business models and corporate strategy. For this reason, patents
have become crucial strategic pieces in business and competitive intelligence in the twenty-first
century. Having the right patents, and even more importantly, knowing how to use them can
either bolster or harm a company. As technology and rapid advancements in innovation become
the cornerstone of corporate success, companies’ research and development (R & D) and patent
spending have become more important than ever.
Companies spend a good deal of time, energy and money assessing and developing their patent
portfolios. Patents are a major component of a company’s assets; while they are independent of
company tangibles, they can be bought, sold, and used as collateral. As a result, patents and
other forms of intellectual property are a growing source of both revenue and defense for many
companies. Patents can of course protect a company’s innovations and creative output, but can
also allow an aggressive company to devour innovative authority in a particular field and
prevent competitors from developing similar products. Many companies invest heavily in
building on a core set of patents, acquiring a larger network of patents, and working towards
carving out a niche in the market.
Patents can be viewed as investments for companies in that competitors must buy licenses to
design products based on or similar to their patents. If competitors are not willing to buy some
form of license or permission, they must “design around” the patent. Many companies are
collecting large profits from licensing revenues. IBM in particular collects about $1 billion per
year (Frier, 2013). Licensing a company’s patent rights to another party is particularly lucrative
when a patented technology has crossover potential in another industry (O'Haver, 2003).
Competitors who do not buy licenses or design around a patent may risk an infringement suit,
which can be an expensive and lengthy process.
Companies often collect patents as a defensive strategy and to allow themselves “breathing
room” in a crowded, competitive market. Apple, for example, holds patents to dozens of
inventions which apply to one or more of their products, including the iPad, iPod, and iPhone
(Purcher, 2013). One patent will often not cover or protect an entire product or service, much
less a line of related products; a complex arrangement and intermingling of patents may
combine to create any given product on the market. Nortel Networks, a defunct Canadian
telecommunications equipment maker, sold more than 6,000 patent assets to Apple, Microsoft
and other technology giants – who beat out Google in this bid – for $4.5 billion in cash in 2011.

Most claimed – and this claim was confirmed by Google’s general counsel – that Google sought
these patents merely as a way to protect themselves and avoid lawsuits.
Not all patents are equal and sheer numbers are not the only variable to consider. The IEEE
Spectrum (the magazine and website of the IEEE, the world’s largest professional organization
devoted to engineering and the applied sciences) publishes annual Patent Power Scorecards,
which rank the top 20 patent-holding entities in each industry segment. The findings published
in the Scorecards are based on quantitative benchmarking of the patent portfolios of more than
5,000 leading commercial enterprises, academic institutions, nonprofit organizations, and
government agencies worldwide. The Scorecards’ authors are careful to note that, in 2013,
newcomers with fewer patents are gaining ground and leveling the playing field with their giant
competitors:
Facebook is far from the only newcomer using quality to punch above its portfolio’s weight…
Within the same Communication/Internet Services category, there’s SeeReal Technologies
(developer of holographic and 3-D display technology) at No. 5 and Cleversafe (provider of
dispersed storage solutions) at No. 7. Looking at other scorecards shows DigitalOptics Corp.
debuting at No. 1 in Semiconductor Manufacturing. This subsidiary of Tessera Technologies
develops imaging systems for smartphones (Thomas & Breitzman, 2013).
The development of markets for IP has created complicated business decisions for many
companies. Both selling a patented product and licensing the IP have evolved into viable and
lucrative options (Al-Aali & Teece, 2013). In this way, patents can be valuable sources of power
and revenue for many organizations.
Patent citation is an area which has undergone much analysis in recent years. A patent citation
is a reference to prior technology upon which a current patent is built or uses. Some of these
citations are added by inventors, others are added by examiners. Some are simply added to
avoid infringement. Patent citations can give evidence to a couple of different aspects of
innovation: 1) the historical relationships between inventions, inventors, and assignees; and, 2)
citation frequency as an indicator of the importance of individual patents. Some patent
historians and analysts claim that patents that are cited by many later patents tend to contain
important ideas which later inventors use and from which they build. A company with a large
number of cited patents is likely to possess technology that is central to developments in its
industry. Many studies have revealed a link between the number of citations and the technical
importance of patents. Obviously, if a company has invested in further developing an idea
disclosed in a previous patent, then proceeding patents typically signify the economic value of
the innovation (Hall, Jaffe, & Trajtenberg, 2005).
Other studies show a strong and clear connection between patent citations and stock valuations.
A number of studies reveal a solid relationship between patent citations, R & D, and basic patent
counts and the market value of firms and companies (Hall, Jaffe, & Trajtenberg, 2005). Some

scholars assert that patent citations are especially effective in predicting stock values when the
knowledge produced in a patent is “reabsorbed” by the inventing firm and evidenced in future
patents. Belenzon comments that “citations on which the firm builds in a future period are
positively related to stock market value, whereas citations on which the firm does not build are
negatively related to market value” (2011). A series of valuable patents is usually the result of a
lengthy and productive period of R & D, which is often followed by a company’s future
commitment and investment in related R & D, further patenting, and a line of successful,
profitable products. Investors tend to appreciate these things and a company’s stock values and
market value of equity often feel the positive effects.
Strong ties between scientific literature, innovation, and patents are important in biotechnology
and pharmaceutical industries. The cost of R & D in the pharmaceutical industry is rapidly
climbing, in part due to increasing regulation, price control, and competition. Yet the number of
new drugs being approved is decreasing. For these reasons, some claim that patents applying to
the biotechnology or pharmaceutical industries should extend beyond 20 years and that these
special extended patents could be issued to “truly innovative products with real social value”
(Duxbury & Tuck, 2008-2009). Similar demands – for special, expanded patent laws – in the
past have centered on the lengthy time taken to bring new products to the market. Because of
the uniqueness of these issues, some executives and legal counsels in these industries are asking
that IP protection be reevaluated. Duxbury and Tuck comment that the current patent system
“does not distinguish between the relatively minor incremental invention on the one hand and
the major breakthrough invention on the other” (2009). IP experts in these industries are
making the claim that the “one size fits all approach” to patenting does not work for the
pharmaceutical and biotechnology fields. Regardless of varying viewpoints, it is generally
acknowledged that patents and IP in general are absolutely crucial to the stability of and to
maintaining solid R & D in these industries. Furthermore, patents play a big role in encouraging
and driving advancement in these industries and in many more. In short, the patent system
should be partially credited for the incredible number of achievements and high level of
innovation in the pharmaceutical and biotechnology sectors.
Although they have acquired a negative reputation, “patent trolls” are non-practicing entities
(NPEs) which enforce patent rights against infringers and attempt to collect licensing fees, but
do not typically manufacture products or services based upon the patent. Some describe it as a
form of rent-seeking. Critics assert that trolls often obtain patent rights as part of bankruptcy
auctions or by doing just enough specific research to patent an idea, without any intention of
ever producing the product, and that their efforts add to the litigiousness of the IP environment
and stifle other companies’ genuine innovation. Estimates vary on the costs that patent trolls
incur on the U.S. economy, but a recent Boston University study showed that patent trolls cost
the U.S. $29 billion in 2011 alone, and that number only accounted for direct legal costs
(O'Rourke, 2013). Others claim that patent trolls are a by-product, not the cause, of problems in
the patent system. These patent analysts suggest that the focus on trolls obscures more complex

and fundamental problems (Lemley & Melamed, 2013). Most trolls target hugely profitable
companies, such as AT&T, Google, Verizon, and Apple; some defend patent trolls by saying that
they level a playing field in which large companies with huge R & D budgets obliterate
competition by overpatenting their innovation and dominating markets. The fact remains that
patent trolls are legal entities in a complex world of intellectual property and will remain on the
scene as long as a profit is to be made.
Patents are key factors in many companies’ asset portfolios and business strategies in the
twenty-first century. Technology is rapidly changing and drastically important to even the most
basic functions in the modern world; this demands that intellectual property issues be addressed
constantly and thoroughly by businesses wishing to remain competitive in global markets.
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